申请人:Ciba-Geigy Corporation
公开号:US04536505A1
公开(公告)日:1985-08-20
Disclosed are compounds of formula I ##STR1## wherein Ar is 3- or 4-pyridyl or 3- or 4-pyridyl substituted by lower alkyl; R.sub.1 is hydrogen, halogen, trifluoromethyl, lower alkyl, hydroxy, acylated or etherified hydroxy, lower alkyl-(thio, sulfinyl or sulfonyl), or two of R.sub.1 on adjacent carbon atoms represent alkylenedioxy; p is 1 or 2; R.sub.2 represents hydrogen or lower alkyl; one of R.sub.3 and R.sub.4 represents hydrogen and the other of R.sub.3 and R.sub.4 represents the group A-B in which A represents alkylene of 1 to 12 carbon atoms, alkynylene or alkenylene of 2 to 12 carbon atoms each, lower alkylene-phenylene, lower alkylene-(thio or oxy)-lower alkylene, lower alkylene-(thio or oxy)-phenylene, lower alkylenephenylene-lower (alkylene or alkenylene), or alkadienylene or 4 to 12 carbon atoms; and B represents carboxy, esterified carboxy, carbamoyl, mono- or di-lower alkylcarbamoyl, cyano, hydroxycarbamoyl, or 5-tetrazolyl; the pyridyl-N-oxides thereof; and pharmaceutically acceptable salts thereof; methods for their synthesis and pharmaceutical compositions thereof. These compounds are useful as selective thromboxane synthetase inhibitors for the treatment of diseases such as cerebral ischaemia, shock, thrombosis and ischaemic heart disease.
本文披露的是I式化合物,其中Ar是3-或4-吡啶基或3-或4-吡啶基被较低烷基取代;R.sub.1是氢、卤素、三氟甲基、较低烷基、羟基、酰化或醚化的羟基、较低烷基-(硫、亚硫酰基或砜基)、或相邻碳原子上的两个R.sub.1代表烯二氧基;p为1或2;R.sub.2代表氢或较低烷基;R.sub.3和R.sub.4中的一个代表氢,另一个代表A-B基团,其中A代表1到12个碳原子的烷基、2到12个碳原子的炔基或烯基、较低烷基-苯基、较低烷基-(硫或氧)-较低烷基、较低烷基-(硫或氧)-苯基、较低烷基苯基-较低(烷基或烯基)、或4到12个碳原子的烯二烯基;B代表羧基、酯化羧基、氨基甲酰基、单或双较低烷基氨基甲酰基、氰基、羟基氨基甲酰基、或5-四唑基;其吡啶基-N-氧化物;以及药学上可接受的盐;它们的合成方法和药物组合物。这些化合物可用作选择性血栓素合成酶抑制剂,用于治疗脑缺血、休克、血栓形成和缺血性心脏病等疾病。